半乳糖凝集素9(GAL9)检测试剂盒(酶联免疫吸附试验法)
ELISA Kit for Galectin 9 (GAL9)
LGALS9; Ecalectin; Lectin,Galactoside-Binding Soluble 9; Tumor antigen HOM-HD-21
- 编号SEA309Ra
- 物种Rattus norvegicus (Rat,大鼠) 相同的名称,不同的物种。
- 实验方法双抗夹心
- 反应时长3h
- 检测范围7.8-500pg/mL
- 灵敏度最小可检测剂量小于等于2.9pg/mL.
- 样本类型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下载 英文说明书 中文说明书
- 规格 48T96T 96T*5 96T*10 96T*100
- 价格 ¥ 2873 ¥ 4104 ¥ 18468 ¥ 34884 ¥ 287280
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
本试剂盒用于检测半乳糖凝集素9(GAL9),经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的半乳糖凝集素9(GAL9)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。
样本 | 回收率范围(%) | 平均回收率(%) |
serum(n=5) | 97-105 | 101 |
EDTA plasma(n=5) | 97-105 | 102 |
heparin plasma(n=5) | 82-105 | 90 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
批内差: CV<10%
批间差: CV<12%
线性
在定值血清及血浆样本内加入适量的半乳糖凝集素9(GAL9),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中半乳糖凝集素9(GAL9)含量的测定值与理论值的比率。
样本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 84-96% | 80-96% | 83-96% | 87-101% |
EDTA plasma(n=5) | 96-105% | 86-96% | 82-99% | 95-103% |
heparin plasma(n=5) | 83-104% | 79-89% | 80-101% | 79-93% |
稳定性
经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本的准备;
2. 加样(标准品及样本)100µL,37°C孵育1小时;
3. 吸弃,加检测溶液A100µL,37°C孵育1小时;
4. 洗板3次;
5. 加检测溶液B100µL,37°C孵育30分钟;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分钟;
8. 加终止液50µL,立即450nm读数。
实验原理
将半乳糖凝集素9(GAL9)抗体包被于96孔微孔板中,制成固相载体,向微孔中分别加入标准品或标本,其中的半乳糖凝集素9(GAL9)与连接于固相载体上的抗体结合,然后加入生物素化的半乳糖凝集素9(GAL9)抗体,将未结合的生物素化抗体洗净后,加入HRP标记的亲和素,再次彻底洗涤后加入TMB底物显色。TMB在过氧化物酶的催化下转化成蓝色,并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的半乳糖凝集素9(GAL9)呈正相关。用酶标仪在450nm波长下测定吸光度(O.D.值),计算样品浓度。
增值服务
相关产品
编号 | 适用物种:Rattus norvegicus (Rat,大鼠) | 应用(仅供研究使用,不用于临床诊断!) |
RPA309Ra02 | 半乳糖凝集素9(GAL9)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA309Ra01 | 半乳糖凝集素9(GAL9)活性蛋白 | Cell culture; Activity Assays. |
RPA309Ra01 | 半乳糖凝集素9(GAL9)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA309Ra02 | 半乳糖凝集素9(GAL9)多克隆抗体 | WB; IHC; ICC; IP. |
PAA309Ra01 | 半乳糖凝集素9(GAL9)多克隆抗体 | WB; IHC; ICC; IP. |
LAA309Ra71 | 半乳糖凝集素9(GAL9)多克隆抗体(生物素标记) | WB; IHC; ICC. |
SEA309Ra | 半乳糖凝集素9(GAL9)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA309Ra | 半乳糖凝集素9(GAL9)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
杂志 | 参考文献 |
American Journal of Nephrology | Temporal Increases in Urinary Carboxymethyllysine Correlate with Albuminuria Development in Diabetes [Karger: 328581] |
Clinical Immunology | Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated Th2 cells [ScienceDirect: S1521661611001057] |
Renal Failure | Rat Renal Interstitial Fibroblasts Affect the Th1/Th2 Profile In Vitro [Pubmed: 22013937] |
BMC Nephrol | Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease [PubMed: 23339460] |
Retrovirology | Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection [PubMed: PMC3750478] |
PLoS One. | Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection [PubMed: PMC3480425] |
PLoS Pathogens | Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C [PubMed: PMC3688567] |
PLOS ONE | Graves’ Disease Is Associated with a Defective Expression of the Immune Regulatory Molecule Galectin-9 in Antigen-Presenting Dendritic Cells [PubMed: 25880730] |
Advances in Experimental Medicine and Biology | Molecules of Damage-Associated Patterns in Bronchoalveolar Lavage Fluid and Serum in Chronic Obstructive Pulmonary Disease [Pubmed:29429028] |
Journal of Microbiology, Immunology and Infection | Galectin-9-like from Angiostrongylus cantonensis young adult worms modulates eosinophil chemotaxis in vitro [Doi: 10.1016/j.jmii.2018.09.010] |
Oncology Letters | The effects of Tim‑3 activation on T‑cells in gastric cancer progression [] |
Scientific Reports | Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra … [Pubmed: 31337865] |
Biomolecules | Blood Levels of Galectin-9, an Immuno-Regulating Molecule, Reflects the Severity for the Acute and Chronic Infectious Diseases. Biomolecules 2021, 11, 430 [33804076] |
Medicine | Regulatory T cells, damage-associated molecular patterns, and myeloid-derived suppressor cells in bronchoalveolar lavage fluid interlinked with chronic obstructive … [Pubmed:35687771] |